Glenmark has developed pharmaceutical active ingredients and formula for FabiFlu through internal research and development; DCGI allowed the third stage of fast track trials in a limited number of patients; The approval process is also subject to the Emergency Use Permission
Key points related to Glenmark's FabiFlu-
- Glenmark is the first drug company to receive approval for an oral medication to treat patients with COVID-19 in India
- At a price of Rp 3500 for 34 tablets, the dose is 200 mg x 9 tablets on the first day and 200 mg x 4 tablets per day for 14 days.
- Global experiences show more than 80-88% efficacy. Japan, Bangladesh, and the United Arab Emirates are already using the drug to treat COVID-19
- Among the companies preparing for the launch include Strades Pharma, Brenton Pharmacuticals, Lhasa SuperGenics and Optimus Pharma.
- The API developed by Glenmark's internal R&D unit
Glenmark Pharmaceuticals, the leading pharmaceutical company, has become the first Indian company to commercially launch an antiviral drug, Favipiravir under the brand name FabiFlu, to treat patients with low to moderate COVID-19. The company obtained marketing and manufacturing approval from the Indian Drug Regulator, Drug Controller General of India (DCGI) and launched the product in the Indian market today.
At a price of Rp 3500 for a package of 34 tablets (Rs 103 per tablet), the dose is 200 mg x 9 tablets on the first day and 200 mg x 4 tablets per day for 14 days of treatment. Glenmark performed a clinical trial between 90 patients with moderate to 60 moderate COVID-19 in 11 locations in India. The drug is claimed to be more than 80% effective in treating patients with moderate to moderate COVID-19.
Some other Indian companies that have requested approval and are preparing a launch in India, said the Delhi-based sources, Brenton Pharmacuticals, based in Bengaluru, based in Bengaluru, Lhasa SuperGenerics, Mumbai Optimus Pharma, based in Hyderabad.
Glenmark developed the active pharmaceutical ingredient (API) and formulated FabiFlu through internal research and development. DCGI allowed the third stage of fast track trials in a limited number of patients. The approval process is also subject to the Emergency Use Permission (USA).
India has approximately 4 lakh of COVID-19 patients now, with approximately 13,000 deaths and a death rate of 3.28%. On June 20, 14,516 new cases were reported in India.
Read More: Doctors warn you: Not to do these 5 things when you are out